What Causes Dry Eyes with Endometriosis?

What Causes Dry Eyes with Endometriosis?

Yes, dry eyes are a recognized — and underreported — symptom pattern in endometriosis. Estrogen fluctuation reduces aqueous tear production and destabilizes the meibomian glands that produce the lipid layer of your tear film. Systemic inflammation compounds the problem. The exception: if your dry eyes appeared independently of your cycle or flare patterns, a separate diagnosis (Sjögren's, thyroid disease) may be the primary driver.

Endometriosis is officially a pelvic disease, but its reach extends far beyond the reproductive system. Researchers now classify it as a systemic inflammatory condition, and its effects on ocular surface health are increasingly documented in the ophthalmology and rheumatology literature. If you have endometriosis and wake up with gritty, burning, or light-sensitive eyes — especially around menstruation or after a flare — you are not imagining a connection that does not exist.

How Estrogen Dominance Disrupts Tear Production

The lacrimal gland — the primary producer of the aqueous component of tears — is a sex-hormone-sensitive tissue. It expresses estrogen receptors (ERα and ERβ) and androgen receptors, and the balance between those hormones shapes how well the gland functions.

In endometriosis, the hormonal environment is defined by what clinicians call estrogen dominance: circulating estradiol is elevated relative to progesterone, particularly in the luteal phase. Local estrogen production is also amplified because endometriotic lesions themselves produce aromatase, the enzyme that converts androgens to estrogen (Bulun et al., J Clin Endocrinol Metab 2009; PMID: 19164473).

Here is the paradox that confuses most patients: estrogen is not simply "bad" for the eyes. At physiologically normal levels, estrogen supports lacrimal gland secretion. The problem is the ratio. High estrogen without adequate progesterone, combined with suppressed androgen levels, creates a dysfunctional signaling environment at the lacrimal gland. Androgens — particularly dihydrotestosterone (DHT) — are actually the dominant driver of meibomian gland lipid secretion, which forms the outer, evaporative layer of the tear film. When aromatase overactivity in endometriotic tissue converts androgens to estrogen systemically, circulating androgen levels drop. The meibomian glands respond by producing less lipid, the tear film becomes unstable, and the aqueous layer evaporates faster — a pattern called evaporative dry eye disease (Sullivan et al., Invest Ophthalmol Vis Sci 2002; PMID: 11923260).

This mechanism is not unique to endometriosis. It is the same reason women on GnRH agonist therapy (Lupron, for example) — a common endometriosis treatment that drives estrogen to postmenopausal levels — frequently report severe ocular dryness. The drug suppresses both estrogen and androgens simultaneously, and the meibomian glands pay the price.

For a broader look at how hormonal conditions overlap with ocular surface symptoms, the pattern seen in adenomyosis and dry eyes follows a nearly identical estrogen-androgen disruption pathway.

Systemic Inflammation and the Ocular Surface

Endometriosis is now understood to be driven by chronic, low-grade systemic inflammation. Peritoneal fluid from women with endometriosis contains elevated concentrations of pro-inflammatory cytokines — specifically IL-1β, IL-6, IL-8, and TNF-α — and these are not confined to the pelvis. They circulate (Sikora et al., J Reprod Immunol 2012; PMID: 22542276).

The ocular surface has its own immune surveillance system: conjunctival goblet cells, corneal epithelial cells, and the lacrimal functional unit. When systemic inflammatory cytokines reach the eye, they can trigger a localized inflammatory cascade that disrupts goblet cell density. Goblet cells produce mucin — the innermost layer of the tear film that allows tears to adhere to the corneal surface. Reduced goblet cell density means mucin production falls, tears don't spread evenly, and the classic dry eye symptom complex (burning, grittiness, photophobia, fluctuating vision) emerges even when total tear volume appears adequate on a Schirmer test.

This is why some women with endometriosis test "normal" on basic dry eye screening but still experience significant symptoms. The mucin layer is rarely measured in routine clinical settings. A more sensitive assessment — tear film break-up time (TBUT) or ocular surface staining with lissamine green — often reveals dysfunction that Schirmer misses.

Similar inflammatory mechanisms are at play in dry eyes with PMDD, where neuroinflammatory and hormonal triggers overlap significantly with what happens in endometriosis flares.

Estrogen Dominance Root Causes: Why the Hormonal Imbalance Persists

Understanding why estrogen dominance is so entrenched in endometriosis requires looking at three interconnected systems: local estrogen production, impaired estrogen clearance, and progesterone resistance.

Local estrogen production: As noted above, endometriotic lesions express aromatase at levels far exceeding normal endometrial tissue. This creates a self-sustaining loop — estrogen stimulates lesion growth, lesion growth increases aromatase activity, aromatase produces more estrogen. This feedback is largely independent of ovarian signaling, which is why endometriosis can persist and progress even when ovarian estrogen output is suppressed.

Impaired hepatic clearance: Estrogen is metabolized in the liver via Phase I (CYP1A2, CYP3A4) and Phase II (glucuronidation, sulfation, methylation via COMT) pathways. When these pathways are sluggish — due to nutrient deficiencies, genetic polymorphisms in COMT or MTHFR, or liver burden — estrogen recirculates rather than being excreted. An overloaded gut also contributes: beta-glucuronidase-producing bacteria in the colon can cleave the glucuronide tag from conjugated estrogen, allowing it to be reabsorbed. This is sometimes called the estrobolome effect.

Progesterone resistance: Women with endometriosis frequently show progesterone receptor downregulation in affected tissue, meaning even adequate circulating progesterone fails to counter estrogen's proliferative effects. This is a receptor-level problem, not just a serum-level problem — which is why progesterone supplementation alone often does not fully resolve symptoms.

All three mechanisms sustain the hormonal environment that depletes androgens, dysregulates lacrimal gland function, and drives the inflammatory state that damages the ocular surface. Addressing dry eyes in endometriosis therefore requires working upstream on these root causes, not just applying lubricating drops.

The hormone-eye connection is also well-documented in perimenopause with thyroid dysfunction — a pattern explored in depth at dry eyes in perimenopause with hypothyroidism, where the overlap of thyroid and estrogen dysregulation amplifies ocular surface damage through overlapping mechanisms.

Hashimoto's Root Causes: The Autoimmune Overlap You Should Not Miss

Endometriosis co-occurs with Hashimoto's thyroiditis at rates significantly above population baseline. A 2019 cross-sectional study found the odds of autoimmune thyroid disease were approximately 9.6 times higher in women with endometriosis compared to controls (Nielsen et al., Thyroid 2019). The shared immune dysregulation — particularly Th1/Th2 imbalance and elevated antinuclear antibodies — is the likely common driver.

This matters for dry eyes because Hashimoto's independently causes ocular surface disease through two mechanisms. First, hypothyroid states reduce the metabolic activity of lacrimal and meibomian gland cells, slowing lipid and aqueous secretion directly. Second, Hashimoto's is associated with secondary Sjögren's-like features — autoimmune attack on exocrine glands, including lacrimal tissue — in a subset of patients. When endometriosis and Hashimoto's coexist, the dry eye burden compounds substantially.

Thyroid-specific contributors to dry eyes — including how TSH elevation affects goblet cell function and meibomian lipid composition — are mapped in detail at dry eyes in perimenopause with hypothyroidism.

From a biomarker standpoint, if you have endometriosis and dry eyes that don't respond to hormone-directed interventions, testing TPO antibodies, anti-thyroglobulin antibodies, and a full thyroid panel (TSH, free T3, free T4, reverse T3) is clinically warranted before attributing the symptom solely to endometriosis mechanisms.

The Biomarker Picture: What Lab Work Actually Reveals

Dry eyes in endometriosis don't have a single confirmatory lab marker, but a pattern of findings across several panels tends to emerge in clinical practice:

A low omega-3 index deserves specific attention. A randomized controlled trial of 3g/day EPA+DHA over 12 weeks in dry eye patients demonstrated significant improvement in TBUT and Schirmer scores versus placebo, with the effect attributed to reduction in conjunctival IL-6 and TNF-α (Bhargava et al., Contact Lens Anterior Eye 2015; PMID: 25796346). Given that endometriosis already drives IL-6 and TNF-α elevation systemically, the combined burden on the ocular surface is additive — and omega-3 supplementation addresses both the local inflammatory pathway and the systemic one simultaneously.

Seasonal Allergies Root Causes: The Ocular Mimicry Problem

One reason dry eyes in endometriosis are frequently misdiagnosed is that their presentation closely mimics seasonal allergic conjunctivitis. Both cause itching, redness, tearing, and light sensitivity. The distinction matters because the treatments differ: antihistamine eye drops can actually worsen dry eye disease by reducing tear production further, which makes symptoms deteriorate if the underlying issue is inflammatory dry eye rather than allergic conjunctivitis.

There is also a biological reason why allergic symptoms and endometriosis overlap in the same patients. Mast cells — immune cells that drive allergic responses — are found in abnormally high concentrations in endometriotic lesions. Mast cell activation releases histamine systemically, which can cause conjunctival hyperreactivity that resembles allergic eye disease. Estrogen itself is a mast cell activator, so estrogen dominance in endometriosis can amplify histamine-mediated ocular symptoms on top of the structural tear film deficiency (Theoharides et al., Biochim Biophys Acta 2012; PMID: 22503887).

If your eye symptoms are worst during pollen season and also track with your menstrual cycle, you may be dealing with both conditions simultaneously. An ophthalmologist can differentiate them using conjunctival cytology: allergic conjunctivitis shows eosinophil infiltration; inflammatory dry eye shows neutrophil and lymphocyte predominance with reduced goblet cell density.

The mast cell-histamine axis in hormonal conditions like endometriosis also contributes to symptoms beyond the eyes — the same mechanism drives bloating with endometriosis in a subset of patients with concurrent mast cell reactivity.

Practical Protocol: Addressing the Root Causes Systematically

Managing dry eyes in endometriosis requires working across three levels: reducing systemic inflammation, supporting estrogen metabolism and clearance, and protecting the ocular surface directly.

Step 1 — Ocular surface support (immediate):

• Preservative-free artificial tears, 4–6 times daily (avoid BAK-preserved drops, which worsen goblet cell damage)
• Warm compresses 10 minutes nightly to support meibomian gland function
• Reduce screen time or use the 20-20-20 rule (every 20 minutes, look 20 feet away for 20 seconds)

Step 2 — Anti-inflammatory nutrition:

• Omega-3 fatty acids at 2–3g EPA+DHA daily — the most evidence-supported nutritional intervention for inflammatory dry eye
• Reduce dietary arachidonic acid (processed vegetable oils, grain-fed animal products) which amplifies the same IL-1β/TNF-α cascade driving tear film disruption
• Adequate vitamin D — deficiency is associated with both endometriosis severity and ocular surface disease; target serum 25-OH-D above 40 ng/mL

Step 3 — Estrogen metabolism support:

• DIM (diindolylmethane) at 100–200mg shifts estrogen metabolism toward the less proliferative 2-hydroxyestrone pathway
• B6 and magnesium support COMT and sulfation pathways for hepatic estrogen clearance
• Address gut dysbiosis to reduce beta-glucuronidase activity and estrogen recirculation

Step 4 — Testing-directed intervention:

• If androgen levels are low, discuss DHEA with your provider — low-dose DHEA (25–50mg) can restore meibomian gland function in androgen-deficient dry eye, though endometriosis-specific data is limited
• If TPO antibodies are positive, address thyroid optimization before assuming dry eyes are purely endometriosis-driven
• Recheck hs-CRP and omega-3 index at 3 months to assess response

What This Means for Your Formula

For someone with endometriosis-driven dry eyes, the most targeted nutritional priorities center on resolving the inflammatory and hormonal root causes — not just supplementing for the eye symptom in isolation.

Omega-3 (EPA/DHA): Ones includes pharmaceutical-grade Omega-3 dosed at clinically relevant EPA+DHA levels matching the ranges shown to reduce conjunctival inflammatory markers in RCT evidence (Bhargava et al., 2015; PMID: 25796346). This is one of the few nutritional interventions with direct ocular surface trial data.

Vitamin D3 + K2 (MK-7): Vitamin D deficiency is disproportionately common in endometriosis, with deficiency correlating with higher inflammatory marker levels and more severe disease. Ones pairs D3 with MK-7 to support absorption and direct calcium away from soft tissue — relevant given that endometriosis lesions can calcify in some presentations.

Liver Support (System Blend): Ones' proprietary Liver Support blend is formulated to promote Phase II hepatic detoxification pathways — directly relevant to the estrogen clearance bottleneck described above. Supporting methylation, glucuronidation, and sulfation helps reduce estrogen recirculation and the systemic estrogen excess that drives both lesion activity and ocular androgen depletion.

Because the interaction between these factors is individual — your estradiol:progesterone ratio, your omega-3 index, your inflammatory load — the Ones AI evaluates your lab results and wearable data together to determine which combination of ingredients and doses applies to your specific pattern, rather than applying a generic women's health formula.

Key Takeaways

• Dry eyes in endometriosis are driven by at least three overlapping mechanisms: androgen depletion (meibomian gland dysfunction), estrogen-driven inflammation (goblet cell and lacrimal gland disruption), and systemic cytokine elevation (IL-1β, IL-6, TNF-α).
• The paradox of estrogen's role is important: it is not the absolute level but the ratio — high estrogen relative to progesterone, plus suppressed androgens — that disrupts the tear film.
• Standard Schirmer testing often misses mucin-layer dysfunction; tear film break-up time (TBUT) is a more sensitive measure for this population.
• Hashimoto's thyroiditis co-occurs with endometriosis at roughly 9–10× the population rate; if dry eyes don't respond to hormonal interventions, TPO antibody testing is warranted.
• Omega-3 fatty acids at 2–3g EPA+DHA daily have the strongest nutritional evidence base for inflammatory dry eye, directly relevant to the cytokine environment in endometriosis.
• Seasonal allergy symptoms and endometriosis-driven mast cell histamine release can mimic each other at the ocular surface — antihistamine drops can worsen true dry eye, so differentiation matters before treatment.
• Consult a healthcare provider before initiating any supplement protocol, particularly if you are on GnRH agonist therapy or hormonal endometriosis treatment.